Related Experiment Video
Updated: Oct 11, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
2.0K
Angioedema associated with dipeptidyl peptidase-IV inhibitors
Nicoletta Cassano1, Eustachio Nettis2, Elisabetta Di Leo3
1Dermatology and Venereology Private Practice, Bari and Barletta, Italy.
Clinical and Molecular Allergy : CMA
|December 7, 2021
Summary
Dipeptidyl peptidase-IV (DPP-IV) inhibitors, or gliptins, rarely cause angioedema, especially when combined with ACE inhibitors. Other risk factors may also contribute to this rare side effect.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Safety
Background:
- Dipeptidyl peptidase-IV (DPP-IV) inhibitors (gliptins) are oral antidiabetic agents.
- Postmarketing reports indicate gliptins may increase angioedema risk, particularly with concurrent angiotensin-converting enzyme inhibitor (ACEI) use.
Purpose of the Study:
- To provide an overview of the risk of angioedema associated with gliptin therapy.
Main Methods:
- Literature search of the PubMed database using keywords: "angioedema", "dipeptidyl peptidase", "gliptins", and specific DPP-IV inhibitor names.
- Inclusion of English-language articles published up to December 2020.
Main Results:
- Gliptin monotherapy does not appear to increase angioedema risk.
- A higher susceptibility to angioedema is observed in patients concurrently treated with gliptins and ACEIs.
- Angioedema can occur with DPP-IV inhibitors even without ACEIs, potentially due to other drug interactions or enzyme deficiencies.
Conclusions:
- The risk of angioedema with gliptins is primarily linked to concurrent ACEI use, though it may be underreported.
- Further research is needed on additional risk factors and drug interactions.
- Caution is advised when prescribing DPP-IV inhibitors to patients on ACEIs or with existing angioedema risk factors.
Keywords:
AngioedemaAngiotensin-converting enzyme inhibitorsBradykininDipeptidyl peptidase-IV inhibitorsGliptinsMore Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
282
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
282
01:24Glucagon-like Receptor Agonists
469
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
469
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
1.0K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
308
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
308
01:16Insulin: Dosing Regimen and Adverse Effects
299
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
299
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
336
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
336